A novel Wnt regulatory axis in endometrioid endometrial cancer

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5103-5117

  Zhao, Yu ^a   Yang, Yihua ^a   Trovik, Jone ^b,c   Sun, Kun ^a   Zhou, Liang ^a   Jiang, Peiyong ^a   Lau, Tat San ^a   Hoivik, Erling A ^b,c   Salvesen, Helga B ^b,c   Sun, Hao ^a   Wang, Huating ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CADHERIN; LONG UNTRANSLATED RNA; MALAT1 LONG NON-CODING RNA, HUMAN; PCDH10 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; DNA METHYLATION; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE; WNT SIGNALING PATHWAY; XENOGRAFT;

ANIMALS; APOPTOSIS; BETA CATENIN; CADHERINS; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HETEROGRAFTS; HUMANS; MICE, NUDE; PROMOTER REGIONS, GENETIC; RNA, LONG NONCODING; WNT SIGNALING PATHWAY;

EID: 84907499174     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0427     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007;2:57-85.
3. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
4. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013;62:111-23.
5. Yang Y, Zhou L, Lu L, Wang L, Li X, Jiang P, et al. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene 2013;32:3432-42.
6. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006;25:1070-80.
7. Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H. Non-clustered protocadherin. Cell Adh Migr 2011;5:97-105.
8. Wolverton T, Lalande M. Identification and characterization of three members of a novel subclass of protocadherins. Genomics 2001;76:66-72.
9. Zhong X, Zhu Y, Mao J, Zhang J, Zheng S. Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol 2013;139:485-90.
10. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009;136:640-51 e1.
11. Yu B, Yang H, Zhang C, Wu Q, Shao Y, Zhang J, et al. High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma 2010;57:247-52.
12. Wang KH, Liu HW, Lin SR, Ding DC, Chu TY. Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci 2009;100:2175-80.
13. Tang X, Yin X, Xiang T, Li H, Li F, Chen L, et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark 2012;12:11-9.
14. Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, et al. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer 2009;48:983-92.
15. Lin YL, Li ZG, He ZK, Guan TY, Ma JG. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res 2012;40:2117-23.
16. Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L. Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta 2012;1823:298-305.
17. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, et al. Epigenetic alteration: new insights moving from tissue to plasma-the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer 2013;109:807-13.
18. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071-6.
19. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits prooncogenic activity in pancreatic cancer. Oncogene 2013;32:1616-25.
20. Clark MB, Amaral PP, Schlesinger FJ, Dinger ME, Taft RJ, Rinn JL, et al. The reality of pervasive transcription. PLoS Biol 2011;9:e1000625; discussion e1102.
21. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009;458:223-7.
22. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013;14:699-712.
23. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012;482:339-46.
24. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012;81:145-66.
25. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012;9:703-19.
26. Gutschner T, Hammerle M, Diederichs S. MALAT1-a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 2013;91:791-801.
27. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012;31:4577-87.
28. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003;22:8031-41.
29. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007;26:851-8.
30. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long noncoding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29:1810-6.
31. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G. Inhibition of metastasisassociated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin 2010;42:224-9.
32. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 2011;39:169-75.
33. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, et al. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011;147:773-88.
34. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013;9:e1003368.
35. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclearretained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010;39:925-38.
36. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013;73:1180-9.
37. Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, et al. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 2013;19:1094-105.
38. Heckman KL, Pease LR. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2007;2:924-32.
39. Lu L, Sun K, Chen X, Zhao Y, Wang L, Zhou L, et al. Genome-wide survey by ChIP-seq reveals YY1 regulation of lincRNAs in skeletal myogenesis. EMBO J 2013.
40. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013;4:1628.
41. Dallosso AR, Oster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene 2012;31:4409-19.
42. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome5q31 in Wilms' tumor. PLoS Genet 2009;5:e1000745.
43. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012;149:1192-205.
44. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, et al. Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90.
45. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353-61.
46. Frietze S, Wang R, Yao L, Tak YG, Ye Z, Gaddis M, et al. Cell typespecific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3. Genome Biol 2012;13:R52.
47. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 2004;32(Web Server issue):W217-21.
48. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295-304.
49. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012;8:2289-94.
50. Koshimizu TA, Fujiwara Y, Sakai N, Shibata K, Tsuchiya H. Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line. Life Sci 2010;86:455-60.
51. Leucci E, Patella F, Waage J, Holmstrom K, Lindow M, Porse B, et al. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep 2013;3:2535.